Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 30, 2015 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, commercial-
stage diagnostics company focused on developing and commercializing proprietary
tests for the management of immune-regulated conditions, today announced its
underwritten offering of 4,255,319 ordinary shares priced at $11.75 per share.
The Company has granted the underwriters the option to purchase up to an
additional 638,297 ordinary shares at the public offering price less the
underwriting discount.
J.P. Morgan Securities LLC and Piper Jaffray & Co. are acting as joint book-
running managers for the offering. Cowen and Company, LLC and Robert W. Baird &
Co. Incorporated are acting as co-managers.
The securities described above are being offered by the Company pursuant to a
registration statement previously filed with and declared effective by the
Securities and Exchange Commission (the "SEC"). A preliminary prospectus
supplement and accompanying prospectus relating to the offering have been filed
with the SEC and are available on the SEC's website at www.sec.gov. When
available, copies of the final prospectus supplement and accompanying prospectus
relating to this offering may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, or by telephone at (866) 803-9204, or from Piper Jaffray & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402 or by telephone at (800) 747-3924, or by e-mailing a request to
prospectus(at)pjc.com.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
focused on developing and commercializing proprietary tests for the management
of immune-regulated conditions. The Company's initial product is the T-
SPOT(®).TB test, which is used to test for latent tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The T-SPOT.TB test utilizes the proprietary T-SPOT technology platform
that measures the responses of specific immune cells, known as T cells, to
inform the diagnosis, prognosis and monitoring of patients with immunologically
controlled diseases. The Company has an additional six products based on either
T-SPOT or innate immunity technology platforms in various stages of development.
The two most advanced products are focused on the transplantation market and
test for CMV infection and organ rejection. The Company is headquartered near
Oxford, UK and in Marlborough, MA.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec(at)westwicke.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
[HUG#1890664]
Unternehmensinformation / Kurzprofil:
Datum: 30.01.2015 - 13:00 Uhr
Sprache: Deutsch
News-ID 368142
Anzahl Zeichen: 4519
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
